6260511
doi
10.5281/zenodo.6260511
oai:zenodo.org:6260511
user-eu
user-prefer
Rosanne Janssens
KU Leuven
Isabelle Huys
KU Leuven
Ian Smith
University Medical Centre Utrecht
Charis Girvalaki
European Cancer Patient Coalition
Ardine de Wit
University Medical Centre Utrecht
Jorien Veldwijk
Erasmus University Rotterdam
Lucilla Lanzoni
European Institute of Oncology
Serena Oliveri
European Institute of Oncology
Monica Casiraghi
European Institute of Oncology
Treating non-small cell lung cancer: What do patients PREFER
Meredith Smith
Alexion
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Plain language summary
Case study
<p>We wanted to learn about lung cancer patients’ preferences for new treaments, and what they considered to be the maximum acceptable risk, and the minimum acceptable benefit of a treatment.</p>
Zenodo
2022-02-24
info:eu-repo/semantics/other
6260510
user-eu
user-prefer
award_title=Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966; award_number=115966; award_identifiers_scheme=url; award_identifiers_identifier=https://cordis.europa.eu/projects/115966; funder_id=00k4n6c32; funder_name=European Commission;
1653917846.641257
795397
md5:bb05f24ccc53503147f1ee40dc433d3a
https://zenodo.org/records/6260511/files/Treating non-small cell lung cancer - What do patients PREFER.pdf
public
10.5281/zenodo.6260510
isVersionOf
doi